Vaxcyte, Inc. PCVX Tax on Share Settlement
Tax on Share Settlement at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s tax on share settlement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s tax on share settlement?
- Vaxcyte, Inc. (PCVX) reported tax on share settlement of $9.3M in Q1 2026.
- How has Vaxcyte, Inc.'s tax on share settlement changed year-over-year?
- Vaxcyte, Inc.'s tax on share settlement increased by 75.7% year-over-year, from $5.29M to $9.3M.
- What is the long-term trend for Vaxcyte, Inc.'s tax on share settlement?
- Over 3 years (2022 to 2025), Vaxcyte, Inc.'s tax on share settlement has grown at a 133.7% compound annual growth rate (CAGR), from $861K to $10.99M.
- What does tax on share settlement mean?
- Cash paid to tax authorities for employee share vesting, where the company withholds shares and pays the tax obligation in cash.